DHR Stock Recent News

Danaher faced a disappointing 2024, despite beating Q3 expectations, due to unaltered full-year guidance and a significant asset writedown. The company executed a $4.5 billion share buyback, with an additional 20 million shares authorized, reflecting confidence in long-term growth. Danaher's ROIC appears low due to heavy R&D and capex investments, but this expands its competitive moat and deters new entrants.

In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable dividend stocks thrive despite volatility, offering steady income and solid growth in uncertain times. Building a balanced portfolio of 10 carefully selected SWAN stocks ensures consistent returns. This strategy offers peace of mind, regardless of market fluctuations.

New, Fully Automated, High-Throughput RUO Assays offered on Beckman Coulter Immunoassay Analyzers BREA, Calif. , Jan. 15, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in advanced diagnostics, today announced availability of new Research Use Only (RUO) blood-based biomarker immunoassays designed to advance neurodegenerative disease research.

Danaher Corporation (NYSE:DHR ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2024 2:15 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - J.P.

WASHINGTON , Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2024 performance in a presentation at the J.P.

Seeking Alpha's Quant Valuation and Growth Grades identify 6 blue-chip stocks with extremely high valuations matched against limited operating growth potential. Costco, Cencora, West Pharmaceutical Services, Danaher, Madison Square Garden Sports, and Estée Lauder appear to be at risk of disappointing investors in 2025. Weakening technical performance vs. the S&P 500 is part of the bearish sell/avoid equation for each since summer.

Partnership seeks to improve patient outcomes and experience through novel digital and diagnostic solutions. Investment aligns with Danaher's mission to accelerate the transition to precision medicine with AI-enabled diagnostics.

WASHINGTON , Jan. 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.

Danaher boasts a wide-moat business model with mission-critical products and recurring revenue streams, ensuring a durable competitive advantage and long-term growth potential. The company's disciplined M&A strategy and integration capabilities have driven significant value creation, supported by strong secular healthcare trends and a focus on innovation. Despite a modest 0.5% dividend yield, Danaher's 12.4% five-year CAGR and low payout ratio offer substantial growth potential for total return investors.

Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.